CU6 - ASX Charts, page-2096

Of course this is the chart thread, but since this discussion seems to be moving outside of that subject I'll add my 2 bobs worth too.

I believe any investment decision should be based purely on the fundamentals of the company, the prevailing circumstances and environment within which it operates. Any decision that simply relates to its share price history misses the point of what ultimately underpins the company’s ’s unique reason for being investable.

Charting on the other hand can provide invaluable information on a company's share price momentum, and may provide insight to some particular weakness, issue or concern to the company’s business or activities. This view doesn't just relate to CU6, but to any company for that matter.

Specifically relating to Clarity, and its particular strengths, there is growing evidence that its Cu64 product, linked to the SAR-bisPSMA molecule, provides a substantial improvement in PET imaging, superior to anything else currently available on the market. That market has already proven to be a gold mine for Lantheus and Telix despite inferior (albeit reasonably good) products. As AT has publicly stated, he is not seeking to obtain a share of the diagnostic market, he is expecting to dominate it!

The US diagnostic market alone estimated annually in the billions of dollars provides good reason for CU6 to be a very successful business, at some multiple to its diagnostic market share.
And then there is Cu67 for therapy!

Anyone who doubts the likelihood of CU6 not going multiples of its current mkt cap either has their head in the sand, or is simply talking their own book! I know I am biased, but having been in the market a long time I feel very comfortable holding for the very long term - or until BP takes the stock off me.